Key Takeaways

  • Newton's Neurolens N3 has received CE marking, authorizing commercialization across the European Union and European Economic Area

  • The N3 uses objective eye-tracking measurements to support prescriptions for Neurolens lenses with Contoured Prism technology

  • Newton anticipates launching Neurolens in its first European markets in 2027

Newton announced that its Neurolens N3 measurement system has received CE marking under the European Union Medical Device Regulation (EU MDR), clearing the device for commercialization across Europe.

The Neurolens N3 uses eye-tracking technology to objectively measure ocular alignment at distance and near, providing data used to prescribe Neurolens lenses with Contoured Prism technology. The headset-based system offers a controlled testing environment and an automated assessment that takes several minutes and can be performed by trained staff during routine pretesting.

Neurolens is designed to alleviate symptoms associated with ocular misalignment, including headaches, neck and shoulder pain, and motion sickness.

In a randomized, double-masked, crossover clinical trial published in Translational Vision Science & Technology in 2024, patients experienced an average 5-point reduction in Headache Impact Test-6 (HIT-6) scores after 4 weeks of Neurolens wear. Additionally, a survey of Neurolens wearers found that 90% reported symptom improvement after 60 days.

"CE marking under the MDR is a defining milestone for Newton," said Davis Corley, CEO of Newton. "It reflects the rigor behind our technology and our team, and it opens the door for eye care professionals across Europe to offer their patients a new answer to symptoms they've often lived with for years."

EU MDR certification requires compliance with standards for clinical evidence, quality management, technical documentation, and post-market surveillance.

Newton currently operates in the United States and Canada. 

With the certification, issued by Intertek Medical Notified Body AB, the company expects to introduce Neurolens in its first European markets in 2027, with additional countries to follow. Its planned expansion will provide eye care professionals in Europe access to the N3 measurement system and Neurolens prescription technology.